2021
DOI: 10.1007/s10549-021-06137-3
|View full text |Cite
|
Sign up to set email alerts
|

Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
14
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 18 publications
(15 citation statements)
references
References 18 publications
1
14
0
Order By: Relevance
“…This may be due to the large number of Her-2 negative patients who might have suffered recurrence due to other factors such as expression of other oncogenic proteins, continued use of risk factors, not receiving, or completing radiotherapy etc. Usually, the effect of Her-2 on recurrence has been observed solely on Her-2 positive cohorts to provide a better understanding [ 41 ].…”
Section: Discussionmentioning
confidence: 99%
“…This may be due to the large number of Her-2 negative patients who might have suffered recurrence due to other factors such as expression of other oncogenic proteins, continued use of risk factors, not receiving, or completing radiotherapy etc. Usually, the effect of Her-2 on recurrence has been observed solely on Her-2 positive cohorts to provide a better understanding [ 41 ].…”
Section: Discussionmentioning
confidence: 99%
“…While current treatment guidelines advocate continued HER2-targeted therapy in the adjuvant setting in patients with a pCR [ 8 , 10 ], they generally do not distinguish between single or dual HER2 blockade, likely because these regimens have not been directly compared in this setting in a prospective clinical trial. A recent real-world study of patients with HER2-positive EBC who attained a pCR after treatment with chemotherapy in combination with pertuzumab and trastuzumab in the neoadjuvant setting and who were treated with trastuzumab in the adjuvant setting demonstrated a 90% 4-year EFS rate [ 26 ]. These real-world data are consistent with our pooled analysis from randomized clinical trial data highlighting the risk of recurrence in patients who had attained a pCR and who were subsequently treated with trastuzumab alone in the adjuvant setting.…”
Section: Discussionmentioning
confidence: 99%
“…Other clinical trials in which pertuzumab was added to various chemotherapy backbones had 3-year event free-survival (EFS)-rates ranging from 92 to 94% and 5-year EFS ranging from 82% to 94% [ [12] , [13] , [14] , [15] ]. Previously published comparative real world studies only evaluated pCR or only assessed recurrence-rates in patients achieving a pCR [ [16] , [17] , [18] , [19] ].…”
Section: Discussionmentioning
confidence: 99%